Skip to main content

Table 1 Baseline characteristics of the participants

From: Astaxanthin improves assisted reproductive technology outcomes in poor ovarian responders through alleviating oxidative stress, inflammation, and apoptosis: a randomized clinical trial

Variables

AST (n = 26)

Placebo (n = 25)

P-value

Age (years)

38.42 ± 1.79

38.32 ± 1.67

0.811

BMI (kg/m2)

22.59 ± 1.25

22.46 ± 1.53

0.729

Infertility duration (years)

3.31 ± 1.25

2.88 ± 1.42

0.223

Primary infertility, n (%)

20/26 (76.9%)

17/25 (68.0%)

0.475

Menstrual cycle duration

26.96 ± 3.38

27.44 ± 3.64

0.629

AMH (µg/mL)

0.75 ± 0.16

0.71 ± 0.21

0.368

FSH (mIU/mL)

9.87 ± 1.76

9.95 ± 2.11

0.880

LH (mIU/mL)

4.76 ± 1.17

4.56 ± 1.09

0.523

E2 (pg/mL)

71.63 ± 26.14

68.27 ± 21.89

0.678

P4 (ng/mL)

0.59 ± 0.37

0.53 ± 0.39

0.421

PRL (mIU/L)

200.15 ± 34.50

186.56 ± 28.37

0.132

AFC (n)

4.38 ± 1.41

4.12 ± 1.166

0.365

Adherence rate (%)

98.80 ± 2.01

98.73 ± 2.20

0.945

Blastocyst stage embryo transfer (%)

18/24 (75%)

15/23 (65.2%)

0.464

  1. AST astaxanthin group, BMI body mass index [weight (kg)/height (m2)], AMH anti-müllerian hormone, FSH follicle-stimulating hormone, LH luteinizing hormone, E2 estradiol, P4 progesterone, PRL prolactin, AFC antral follicle count, Adherence rate (Number of dosage units dispensed − number of dosage units remained)/ (prescribed number of dosage unit per day × number of days between 2 visits), n number. Table values represent either mean ± SD or number (percentages). Statistical significance is denoted by a P-value of less than 0.05